Pathological complete response is no surrogate for survival
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pathological complete remission from neoadjuvant therapies is not included as a criterion for clinical benefit because of lack of consistent evidence that it is a valid surrogate for survival.
“Pathological complete remission from neoadjuvant therapies is not included as a criteria for clinical benefit because of lack of consistent evidence that it is a valid surrogate for survival in clinical studies [39][40][41][42].”
Cited by
Sorted by citations
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818 · see citing works
“neo-adjuvant therapies is not included as a criteria for clinical benefit because of lack of consistent evidence that it is a valid surrogate for survival in clinical studies [39-42] by gest on M ay 0, 2015 http://annofordjournals.”
BackgroundCambrosio, A., Bourret, P., Keating, P., & Nelson, N. C. (2017) · Minerva · doi:10.1007/s11024-017-9324-2 · Cited by 23 · see citing works
Reardon, T., Adams, M., Kenzie, N. M., et al. (2008) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.184090
- Authors
- Burki, T. K.
- Corresponding author
- Burki, Talha Khan
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 15
- Issue
- 3
- Pages
- e111
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2045872232
- Cited by
- 2
- References
- 0
- Citations by year
- 2017: 1 · 2015: 1
- FWCI
- 0.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Keywords
- pathological complete response, surrogate endpoints, breast cancer, neoadjuvant chemotherapy, event-free survival, overall survival, pooled analysis, responder analysis, ypN0, treatment response definition
- MeSH terms
- Breast Neoplasms, Female, Humans, Lymphatic Metastasis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
